A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants
Completed · Phase 1 · NCT06937619
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $3.4M
- U.S. investigators named
- 3
- Sites paid
- 2
- Planned or actual enrollment
- 263
About the trial
- Sponsor
- AbbVie
- Tested
- Risankizumab (drug)
- Dates
- Started 2025-04-21; completion 2025-11-10
- Results posted
- Not yet
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.
From ClinicalTrials.gov, last updated 2025-11-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $3.4M in research payments for this study in 2025 (41 payments).
Products named: Skyrizi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Steven H. Reynolds, D.O. Family Medicine · Long Beach, CA
- Peter J. Winkle, MD Gastroenterology · Cypress, CA
- Juan C. Rondon, MD Internal Medicine · Hollywood, FL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cenexel Clinical Research Inc $2.6M
- Erg Holding Company LLC $799,065
- $270
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.